7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart

Key Takeaways Explain This Topic AI

The primary hemodynamic goals of temporary mechanical circulatory support (tMCS) are reducing left ventricular afterload, decreasing end-diastolic wall tension and volume, diminishing myocardial oxygen consumption (MVO_2), and augmenting systemic and coronary perfusion pressure.

The Intra-Aortic Balloon Pump (IABP) functions via counterpulsation: rapid balloon inflation during diastole at the dicrotic notch augments coronary perfusion, while rapid deflation during isovolumetric contraction immediately prior to systole decreases LV afterload, stroke work, and myocardial oxygen demand.

The landmark randomized IABP-SHOCK II trial demonstrated that routine insertion of an IABP in acute myocardial infarction complicated by cardiogenic shock provides no 30-day or long-term mortality benefit compared with optimal medical therapy; routine IABP in AMI-CS is Class 3 (no benefit), and IABP is reserved mainly for mechanical complications (acute MR, VSD) or as a bridge to definitive therapy.

The Impella microaxial transvalvular continuous-flow pump aspirates blood directly from the LV cavity and expels it into the ascending aorta, delivering 2.5 to 5.5 L/min of forward flow, directly unloading the left ventricle, and shifting the ventricular pressure-volume loop leftward and downward.

Key complications of tMCS include device-induced mechanical hemolysis, severe vascular access injury with acute lower limb ischemia, acquired von Willebrand syndrome bleeding, cannula malposition, and aortic valve perforation; TandemHeart bypasses the LV via transseptal left atrial cannulation but requires structural transseptal puncture expertise.

Last updated: October 2026

In cardiogenic shock, profound primary myocardial dysfunction triggers a self-reinforcing downward spiral: falling cardiac output lowers mean arterial pressure and coronary perfusion pressure, inducing further myocardial ischemia. Compensatory systemic vasoconstriction raises afterload, while elevated ventricular filling pressures increase wall tension and myocardial oxygen consumption ( M VO 2 M\text{VO}_2 M VO 2 ​ ). Temporary mechanical circulatory support (tMCS) devices are deployed to break this cycle by uncoupling systemic perfusion from native ventricular stroke work, decreasing intracardiac filling pressures, and augmenting coronary and vital organ blood flow.

1. Hemodynamic Objectives & Pressure-Volume Loop Dynamics

The fundamental physiological objectives of tMCS include:

Unloading the Ventricle: Reducing left ventricular end-diastolic volume (LVEDV) and pressure (LVEDP), which lowers wall stress according to Laplace's Law ( σ = P ⋅ r 2 h \sigma = \frac{P \cdot r}{2h} σ = 2 h P ⋅ r ​ ). Lower wall stress relieves subendocardial microvascular compression and diminishes myocardial oxygen demand ( M VO 2 M\text{VO}_2 M VO 2 ​ ).

Augmenting Systemic Perfusion: Increasing mean arterial pressure, effective cardiac output, and cardiac power output ( CPO = MAP × CO 451 \text{CPO} = \frac{\text{MAP} \times \text{CO}}{451} CPO = 451 MAP × CO ​ ), thereby reversing end-organ hypoperfusion and lactic acidosis.

Elevating Coronary Perfusion Pressure: Enhancing the diastolic pressure gradient across the coronary bed ( CPP = Aortic Diastolic Pressure − LVEDP \text{CPP} = \text{Aortic Diastolic Pressure} - \text{LVEDP} CPP = Aortic Diastolic Pressure − LVEDP ). Pressure-Volume (PV) Loop Dynamics under Mechanical Circulatory Support:

• Pressure
• ^
• | Native LV (Shock) IABP Counterpulsation Impella Microaxial Unloading
• | ┌────────────────┐ ┌───────────────┐ ┌────────┐
• | │ │ │ │ │ │
• | │ High Afterload│ │ Lower Presyst │ │ │ Continuous
• | │ High LVEDP │ │ Reduced Work │ │ Narrow │ Aspiration
• | │ │ │ │ │ Loop │ Shifts PV Loop
• | └────────────────┘ └───────────────┘ └────────┘ Down & Left
• +──────────────────────────> ─────────────────> ─────────>
• Volume Volume Volume
• 2. Intra-Aortic Balloon Pump (IABP)

The Intra-Aortic Balloon Pump is the most widely utilized and historically established tMCS device. It consists of a dual-lumen balloon catheter (balloon volumes 30 – 50 mL 30\text{--}50\text{ mL} 30 – 50 mL ) inserted retrogradely through the common femoral artery into the descending thoracic aorta. Its tip is positioned 1 to 2 cm 1\text{ to }2\text{ cm} 1 to 2 cm distal to the origin of the left subclavian artery , terminating proximally above the celiac and renal arterial take-offs.

The Physiology of Diastolic Counterpulsation

The IABP relies on shuttle gas (helium, chosen for low molecular weight and low viscosity, enabling rapid displacement) synchronized with the cardiac cycle:

Diastolic Inflation (Diastolic Augmentation):

Timing: Rapid inflation occurs precisely at the dicrotic notch on the arterial waveform, signaling aortic valve closure and the onset of diastole.

Hemodynamic Mechanism: The expanding balloon abruptly displaces 30 – 50 mL 30\text{--}50\text{ mL} 30 – 50 mL of blood retrogradely into the ascending aorta and aortic root, generating a prominent diastolic augmentation peak that substantially elevates coronary and cerebral perfusion pressure.

Systolic Deflation (Presystolic Afterload Reduction):

Timing: Rapid deflation occurs immediately prior to ventricular systole, during isovolumetric contraction (corresponding to the peak of the R-wave on surface ECG or just prior to the arterial systolic upstroke).

Hemodynamic Mechanism: Sudden evacuation of helium creates a transient vacuum or suction effect in the aorta. Aortic end-diastolic pressure drops precipitously, markedly reducing the impedance (afterload) against which the left ventricle must eject. Isovolumetric contraction time is shortened, stroke work is diminished, and LV myocardial oxygen consumption drops by 10 % to 15 % 10\%\text{ to }15\% 10% to 15% .

Waveform Interpretation & Critical Timing Errors

Synchronizing IABP inflation and deflation is essential. Inaccurate timing compromises hemodynamic efficacy and can induce catastrophic afterload spikes: IABP Arterial Waveform Timing Comparison:

• Pressure
• ^ Normal Counterpulsation Late Deflation Error
• | [ Diastolic Augmentation ] [ Prolonged Balloon Inflation ]
• | /\ /\
• | /\ / \ /\ / \ /\ [ Impeded Native
• | / \ / \ / \ / \/ \ Ejection ]
• | / \ / \ / \ / \
• | / \_____/ \ / \________/ \
• | / Systole Dicrotic \ Assisted / Systole Dicrotic Assisted
• | / Notch \ Systole / Notch Systole
• +───┴───────────────────────────┴──────────> ┴──────────────────────────────┴───────> Time

Early Inflation: Balloon inflates before the dicrotic notch, encroaching on active systole. The aortic valve is forced shut prematurely, elevating LV afterload, worsening mitral regurgitation, and reducing stroke volume.

Late Inflation: Inflation occurs well after the dicrotic notch. The diastolic augmentation peak is truncated and rounded, resulting in sub-optimal coronary perfusion augmentation.

Early Deflation: Balloon deflates prematurely during mid-to-late diastole. The diastolic augmentation wave decays rapidly, retrograde coronary blood steal may occur, and the afterload-reducing vacuum effect is lost prior to ventricular contraction.

Late Deflation: Balloon remains inflated when ventricular systole begins. The native LV is forced to eject against an occluded aorta, producing a massive spike in presystolic afterload, severe elevation in LV wall stress, and reduction in cardiac output.

Evidence: The IABP-SHOCK II Trial & Guideline Reclassifications

For decades, IABP counterpulsation was considered mandatory first-line therapy for acute myocardial infarction complicated by cardiogenic shock (AMI-CS). However, clinical practice changed radically following the landmark IABP-SHOCK II Trial (Thiele et al., NEJM 2012) :

Study Design: 600 patients with AMI complicated by cardiogenic shock undergoing early revascularization (primarily primary PCI) were randomized to routine IABP insertion versus medical therapy without IABP.

Primary Outcome: 30-day all-cause mortality was identical: 39.7 % 39.7\% 39.7% in the IABP group versus 41.3 % 41.3\% 41.3% in the control group (relative risk 0.96; p = 0.69 p = 0.69 p = 0.69 ).

Long-Term Follow-up: Subsequent 12-month and 6-year follow-up analyses confirmed no difference in all-cause mortality, recurrent infarction, stroke, or repeat revascularization.

Guideline Revisions: In response to IABP-SHOCK II, both ACC/AHA and European Society of Cardiology (ESC) guidelines downgraded routine IABP in AMI-CS to Class III (No Benefit / Routine Use Not Recommended) .

Remaining Valid Indications: IABP retains a Class IIa recommendation (ESC 2023) as a bridge in mechanical complications of acute myocardial infarction, specifically acute mitral regurgitation due to papillary muscle rupture and ventricular septal defect (VSD) , serving as an afterload-reducing stabilizer prior to emergency surgical repair.

Contraindications to IABP

Moderate-to-Severe Aortic Regurgitation: Diastolic balloon inflation forces high-pressure blood retrogradely across the incompetent aortic valve into the LV cavity, causing acute, massive LV overdistension, pulmonary edema, and electromechanical dissociation.

Aortic Dissection or Severe Thoracic/Abdominal Aneurysm: Risk of intimomedial tearing, false lumen expansion, or catastrophic aortic rupture.

Severe Peripheral Artery Disease or Femoral Bypass Grafting.

3. Impella Microaxial Transvalvular Assist Devices

The Impella system represents an active, continuous-flow microaxial pump mounted on a catheter platform. Positioned retrogradely across the aortic valve using fluoroscopic and transesophageal echocardiographic guidance, its inlet rests within the LV cavity (mid-cavity, 4 – 4.5 cm 4\text{--}4.5\text{ cm} 4 – 4.5 cm below the aortic valve, pointed toward the LV apex), while its outlet sits in the ascending aorta. Impella Microaxial Transvalvular Blood Flow Architecture:

• [ Ascending Aorta ]
• ▲
• │ Blood Expelled at Outlet (P-Level Continuous Flow)
• [ Motor Unit ]
• ▲
• =================== [ Aortic Valve Plane ]
• ▲
• [ Cannula ]
• ▲
• │ Blood Aspirated at Inlet
• [ Left Ventricular Cavity ]
• Mechanism of Action & Hemodynamics

The internal Archimedes screw motor spins at speeds up to 45,000 RPM , drawing blood continuously from the LV cavity and discharging it into the ascending aorta.

Direct Mechanical LV Unloading: Unlike IABP (which requires native ventricular ejection to generate stroke volume), Impella provides direct, active forward output independent of myocardial contraction. It directly evacuates blood from the LV, reducing LVEDV, LVEDP, and LV wall stress, while simultaneously elevating mean arterial pressure and cardiac output.

PV Loop Transformation: Impella shifts the left ventricular pressure-volume loop leftward and downward , transforming the rectangular or trapezoidal loop into a narrow, triangular contour with an extinguished or shortened isovolumetric phase, substantially shrinking the pressure-volume area (PVA) and drastically reducing myocardial oxygen consumption.

Impella Device Models & Specifications

Impella 2.5: 12 Fr microaxial pump delivering up to 2.5 L/min 2.5\text{ L/min} 2.5 L/min flow; inserted percutaneously via a 13 Fr femoral sheath.

Impella CP (Cardiac Power): 14 Fr pump delivering up to 3.5 – 4.0 L/min 3.5\text{--}4.0\text{ L/min} 3.5 – 4.0 L/min flow; inserted percutaneously via a 14 Fr peel-away femoral sheath. Standard platform for high-risk PCI and early cardiogenic shock.

Impella 5.0 / 5.5 with SmartAssist: Surgical microaxial pumps delivering up to 5.0 to 5.5 L/min 5.0\text{ to }5.5\text{ L/min} 5.0 to 5.5 L/min of full circulatory support. Impella 5.5 is inserted via an axillary or subclavian cutdown through an end-to-side vascular graft, completely avoiding femoral access and permitting patient extubation, physical rehabilitation, and ambulation as a bridge to recovery or durable LVAD/transplantation.

Impella RP: Percutaneous microaxial pump designed for isolated right ventricular failure , aspirating blood from the inferior vena cava and discharging it into the main pulmonary artery across the tricuspid and pulmonic valves at flows up to 4.0 L/min 4.0\text{ L/min} 4.0 L/min .

Clinical Management, Alarms & Complications

Suction Alarms & Cannula Malposition: If the inlet cannula abuts the ventricular endocardium, papillary muscles, or interventricular septum, or if severe right ventricular failure or hypovolemia diminishes LV preload, the pump cavitates, triggering a "suction alarm". The console automatically down-regulates pump performance level (P-level). Management requires volume expansion, treatment of RV failure, or echocardiographic repositioning of the catheter.

Mechanical Hemolysis: Extreme rotational shear stress across the high-speed microaxial impeller induces mechanical destruction of circulating erythrocytes. Monitored via serial plasma free hemoglobin ( > 40 – 50 mg/dL > 40\text{--}50\text{ mg/dL} > 40 – 50 mg/dL ), serum lactate dehydrogenase (LDH), and dark red/tea-colored urine (hemoglobinuria) that can induce acute tubular necrosis.

Vascular Access Ischemia & Distal Perfusion: Large-bore (14 Fr) femoral sheaths can occlude the superficial or common femoral artery, particularly in patients with peripheral vascular disease, causing acute lower extremity ischemia. Distal perfusion monitoring (pulse oximetry on the great toe, continuous Doppler interrogation) is mandatory.

Bleeding & Acquired von Willebrand Syndrome: High shear forces across the impeller cleave high-molecular-weight multimers of von Willebrand factor, causing acquired von Willebrand disease and severe mucosal or puncture-site bleeding.

Aortic Valve Trauma & Ventricular Arrhythmias: Cannula contact with the aortic valve leaflets or subvalvular apparatus can induce chordal rupture, acute aortic insufficiency, or intractable ventricular tachycardia.

Contraindications: Mechanical aortic valve prosthesis, severe aortic stenosis (impedes catheter crossing and risks calcific embolization), moderate-to-severe aortic regurgitation, and documented left ventricular thrombus (high risk of fatal systemic embolization).

Evidence: The DanGer Shock Trial

The DanGer Shock trial (Møller et al., NEJM 2024) randomized 360 patients (355 analyzed) with STEMI complicated by cardiogenic shock (lactate ≥ 2.5 mmol/L \ge 2.5\text{ mmol/L} ≥ 2.5 mmol/L , LVEF < 45 % < 45\% < 45% ; comatose out-of-hospital arrest and predominant RV shock excluded) to routine Impella CP plus standard care or standard care alone:

Primary outcome: 180-day all-cause death 45.8% vs. 58.5% (hazard ratio 0.74, 95% CI 0.55-0.99; p = 0.04 p = 0.04 p = 0.04 ), an NNT of about 8.

Harms: The composite of severe bleeding, limb ischemia, hemolysis, device failure, or worsening aortic regurgitation occurred in 24.0% vs. 6.2%, and renal replacement therapy was more frequent (41.9% vs. 26.7%).

Guideline impact: The 2025 ACC/AHA/multisociety ACS guideline makes the microaxial flow pump a Class 2a option for selected patients with STEMI and severe or refractory cardiogenic shock, while routine IABP remains Class 3 (no benefit) .

The result applies to a selected STEMI-CS population; it does not establish benefit for unselected cardiogenic shock, heart failure-related shock, or comatose arrest survivors.

SCAI SHOCK Stages

The Society for Cardiovascular Angiography and Interventions (SCAI) staging system (2019, updated 2022) grades shock severity and helps match escalation to risk:

• SCAI Stage Description Typical Findings
• A - At risk No shock yet; at risk (large MI, decompensated HF) Normal BP, normal perfusion
• B - Beginning Hypotension or tachycardia without hypoperfusion Lactate normal, warm extremities

C - Classic Hypoperfusion needing intervention beyond fluids (inotrope, vasopressor, or MCS) Lactate ≥ 2 \ge 2 ≥ 2 , oliguria, cool skin

D - Deteriorating Failing to respond to initial interventions; escalating support Rising lactate despite therapy

E - Extremis Refractory shock, cardiac arrest with ongoing CPR or ECMO Multiple devices or drugs, near-circulatory collapse

Mortality rises steeply from stage C to E, and a modifier is added for cardiac arrest with coma.

4. TandemHeart: Left Atrial-to-Femoral Arterial Bypass

The TandemHeart is an extracorporeal continuous-flow centrifugal pump system that unloads the left heart by aspirating blood from the left atrium and returning it into the arterial system:

Cannulation Architecture:

Venous Drainage Cannula ( 21 Fr 21\text{ Fr} 21 Fr ): Inserted via the femoral vein, advanced through the inferior vena cava, and passed across the interatrial septum into the left atrium via fluoroscopic and transesophageal echocardiography (TEE)-guided transseptal puncture.

Arterial Reinfusion Cannula ( 15 – 17 Fr 15\text{--}17\text{ Fr} 15 – 17 Fr ): Positioned in the contralateral common femoral artery, discharging blood into the abdominal and thoracic aorta.

Hemodynamic Effects: Provides up to 3.5 – 4.0 L/min 3.5\text{--}4.0\text{ L/min} 3.5 – 4.0 L/min of systemic blood flow. By directly evacuating oxygenated blood from the left atrium, it effectively decompresses the left heart, reducing left atrial pressure, PCWP, LVEDP, and LV volume. Unlike Impella, TandemHeart does not cross the aortic valve or enter the LV cavity, making it safe in patients with aortic stenosis, severe aortic regurgitation, or left ventricular thrombus.

Technical Challenges & Risks: Requires specialized interventional cardiology expertise for emergency transseptal puncture in an unstable patient. Potential catastrophic complications include left atrial or aortic root perforation with cardiac tamponade, cannula dislodgement into the right atrium (which converts the circuit into a massive right-to-left shunt producing severe refractory hypoxemia), and a persistent residual atrial septal defect (ASD) following decannulation.

5. Comprehensive MCS Devices Comparison Table

Parameter Intra-Aortic Balloon Pump (IABP) Impella CP Impella 5.5 TandemHeart

Mechanism / Flow Type Pneumatic counterpulsation (diastolic inflation, presystolic deflation) Microaxial continuous-flow transvalvular Archimedes screw Microaxial continuous-flow transvalvular Archimedes screw Extracorporeal continuous-flow centrifugal pump

Cannulation / Access 7 – 8 Fr 7\text{--}8\text{ Fr} 7 – 8 Fr via common femoral artery 14 Fr 14\text{ Fr} 14 Fr sheath via common femoral artery 21 Fr 21\text{ Fr} 21 Fr via axillary/subclavian surgical cutdown 21 Fr 21\text{ Fr} 21 Fr venous (transseptal LA) + 15 – 17 Fr 15\text{--}17\text{ Fr} 15 – 17 Fr femoral arterial

Maximal Support Flow 0.5 – 1.0 L/min 0.5\text{--}1.0\text{ L/min} 0.5 – 1.0 L/min equivalent hemodynamic benefit Up to 3.5 – 4.0 L/min 3.5\text{--}4.0\text{ L/min} 3.5 – 4.0 L/min Up to 5.5 – 6.0 L/min 5.5\text{--}6.0\text{ L/min} 5.5 – 6.0 L/min Up to 3.5 – 4.0 L/min 3.5\text{--}4.0\text{ L/min} 3.5 – 4.0 L/min

LV Preload / LVEDP Modest reduction (indirect) Markedly decreased (direct aspiration) Markedly decreased (direct aspiration) Markedly decreased (direct LA drainage)

LV Afterload Decreased ( 10 % to 15 % 10\%\text{ to }15\% 10% to 15% reduction) Decoupled; increased mean aortic pressure Decoupled; increased mean aortic pressure Decoupled; increased mean aortic pressure

Myocardial M VO 2 M\text{VO}_2 M VO 2 ​ Modestly decreased Substantially decreased Substantially decreased Substantially decreased

Aortic Valve Cross No (descending aorta) Yes (transvalvular LV to aorta) Yes (transvalvular LV to aorta) No (transseptal into LA)

Primary Clinical Hazards Limb ischemia, aortic dissection, balloon rupture Hemolysis, limb ischemia, bleeding (acquired vWD), migration Axillary wound bleeding, stroke, hemolysis Tamponade from transseptal puncture, cannula migration, residual ASD

Absolute Contraindications Aortic regurgitation ( ≥ \ge ≥ moderate), aortic dissection Mechanical aortic valve, LV thrombus, severe AR Mechanical aortic valve, LV thrombus, severe AR Ventricular septal defect, severe peripheral vascular disease